Phase I Clinical Study in the Treatment of HER2-positive Recurrent or Metastatic Breast Cancer.

Condition:   HER2-positive Breast Cancer Intervention:   Biological: Recombinant anti-HER2 humanized monoclonal antibody conjugate for injection.R&D code: B003. Sponsors:   Shanghai Pharmaceuticals Holding Co., Ltd;   Shanghai Jiaolian Medicine Research and Development Co., Ltd. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials